发明名称 |
Targeting trastuzumab-resistant HER2+breast cancer with a HER3-targeting nanoparticle |
摘要 |
Disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to treatment with an anti-HER2 therapy; and administering to the patient a drug delivery molecule, comprising a polypeptide molecule adapted to target and/or penetrate a type of cell; a nucleic acid molecule bound to the polypeptide sequence via electrostatic interactions; and a chemical agent non- covalently linked to the nucleic acid sequence. Also disclosed are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with the drug delivery molecule. Further disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to anti-HER2 therapy; and administering to the patient a therapeutically effective amount of a drug delivery molecule, comprising a polypeptide molecule adapted to target and/or penetrate a type of cell; and a sulfonated corrole molecule bound to the polypeptide sequence. Finally disclosed herein are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with a drug delivery molecule, comprising a polypeptide molecule adapted to target and/or penetrate a type of cell; and a sulfonated corrole molecule bound to the polypeptide sequence |
申请公布号 |
AU2015240460(A1) |
申请公布日期 |
2016.09.15 |
申请号 |
AU20150240460 |
申请日期 |
2015.04.04 |
申请人 |
CEDARS-SINAI MEDICAL CENTER |
发明人 |
MEDINA-KAUWE, LALI K.;SIMS, JESSICA;TAGUAIM, MICHAEL;HANSON, CHRIS;CUI, XIAOJIANG |
分类号 |
A61K47/48;A61K31/555;A61K48/00;A61P35/00 |
主分类号 |
A61K47/48 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|